Visiox Pharma is a biopharmaceutical service provider focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases requiring new treatment options, with key products including PDP-716 and SDN-037. Visiox Pharma announced today that it has closed a $7 million seed round from an exclusive group of founding partners and ophthalmology industry leaders.
This article is reproduced from: https://www.itjuzi.com/investevent/13451558
This site is for inclusion only, and the copyright belongs to the original author.